Switch theme
Sign up to access all valuation multiples
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
2015
171
LTM Revenue $0.7M
LTM EBITDA -$193M
-$162M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pliant Therapeutics has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of -$193M.
In the most recent fiscal year, Pliant Therapeutics achieved revenue of n/a and an EBITDA of -$205M.
Pliant Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pliant Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$193M | XXX | -$205M | XXX | XXX | XXX |
| EBITDA Margin | -28004% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$201M | XXX | -$228M | XXX | XXX | XXX |
| EBIT Margin | -29131% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$186M | XXX | -$210M | XXX | XXX | XXX |
| Net Margin | -26941% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pliant Therapeutics's stock price is $1.
Pliant Therapeutics has current market cap of $83.5M, and EV of -$162M.
See Pliant Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$162M | $83.5M | XXX | XXX | XXX | XXX | $-3.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pliant Therapeutics has market cap of $83.5M and EV of -$162M.
Pliant Therapeutics's trades at -102.5x EV/Revenue multiple, and 0.8x EV/EBITDA.
Equity research analysts estimate Pliant Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pliant Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for Pliant Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $83.5M | XXX | $83.5M | XXX | XXX | XXX |
| EV (current) | -$162M | XXX | -$162M | XXX | XXX | XXX |
| EV/Revenue | -234.9x | XXX | -102.5x | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBIT | 0.8x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | -234.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPliant Therapeutics's last 12 month revenue growth is 142%
Pliant Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Pliant Therapeutics's rule of 40 is -9873% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pliant Therapeutics's rule of X is -27650% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pliant Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 142% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -28004% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | -9873% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -27650% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pliant Therapeutics acquired XXX companies to date.
Last acquisition by Pliant Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Pliant Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pliant Therapeutics founded? | Pliant Therapeutics was founded in 2015. |
| Where is Pliant Therapeutics headquartered? | Pliant Therapeutics is headquartered in United States of America. |
| How many employees does Pliant Therapeutics have? | As of today, Pliant Therapeutics has 171 employees. |
| Who is the CEO of Pliant Therapeutics? | Pliant Therapeutics's CEO is Dr. Bernard Coulie, M.B.A.,M.D.,PhD. |
| Is Pliant Therapeutics publicy listed? | Yes, Pliant Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Pliant Therapeutics? | Pliant Therapeutics trades under PLRX ticker. |
| When did Pliant Therapeutics go public? | Pliant Therapeutics went public in 2020. |
| Who are competitors of Pliant Therapeutics? | Similar companies to Pliant Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pliant Therapeutics? | Pliant Therapeutics's current market cap is $83.5M |
| What is the current revenue of Pliant Therapeutics? | Pliant Therapeutics's last 12 months revenue is $0.7M. |
| What is the current revenue growth of Pliant Therapeutics? | Pliant Therapeutics revenue growth (NTM/LTM) is 142%. |
| What is the current EV/Revenue multiple of Pliant Therapeutics? | Current revenue multiple of Pliant Therapeutics is -234.9x. |
| Is Pliant Therapeutics profitable? | Yes, Pliant Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pliant Therapeutics? | Pliant Therapeutics's last 12 months EBITDA is -$193M. |
| What is Pliant Therapeutics's EBITDA margin? | Pliant Therapeutics's last 12 months EBITDA margin is -28004%. |
| What is the current EV/EBITDA multiple of Pliant Therapeutics? | Current EBITDA multiple of Pliant Therapeutics is 0.8x. |
| What is the current FCF of Pliant Therapeutics? | Pliant Therapeutics's last 12 months FCF is -$161M. |
| What is Pliant Therapeutics's FCF margin? | Pliant Therapeutics's last 12 months FCF margin is -23305%. |
| What is the current EV/FCF multiple of Pliant Therapeutics? | Current FCF multiple of Pliant Therapeutics is 1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
